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Abstract 
Review on DGKA, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: DAGK, DAGK1, DGK-alpha 
HGNC (Hugo): DGKA 
Location: 12q13.2 
Local order  
GSTP1-WIBG-DGKA-PMEL-CDK2. 
Note 
Diacylglycerol kinase alpha (DGKA) is a lipid 
kinase that phosphorylates the lipid diacylglycerol 
(DAG), transforming it into phosphatidic acid (PA). 
DGKA is classified as a type I DGK, characterized 
by possessing EF-hand motifs, which allow calcium 
mediated regulation. DGKA has been characterized 
as a negative regulator of Ras-MAPK pathway in T 
lymphocytes.  
DGKA has a dual role in cancer; it exhibits 
properties similar to a tumor suppressor and has 
also a positive role in the maintenance of cancerous 
states.  
DGKA function might be crucial in the genesis and 
development of several pathologies. 
DNA/RNA 
Note 
DGKA gene is highly expressed in thymus, spleen, 
testis and lung (Sanjuan et al., 2001). DGKA 
displays alternative splicing; numerous splice 
variants are predicted, including truncated forms of 
the protein as well as RNAs with introns retained 
(Martínez-Moreno et al., 2012). The expression of 
some of these transcripts might be related to certain 
pathologies (Batista et al., 2013). 
 
Figure 1. The DGKA gene is located at chromosome 12. It contains 24 exons and the translation initiator ATG is located at 
Exon 2. 
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Figure 2. Putative regulatory elements in the DGKA gene. Transcription initiation sites are indicated (arrows). The +1 position 
was assigned in the Inr element. Putative binding sites for transcription factors are indicated by rectangles; FoxO sites are gray 
(Adapted from Martinez-Moreno et al., 2012). 
 
Transcription 
The DGKA gene encodes a protein of 80 KDa. 
Presence of regulatory regions in the gene was early 
suggested to restrain the expression of DGKA to 
certain tissues (Fujikawa et al., 1993).  
DGKA gene displays alternative use of promoter 
regions, in homology with the mouse gene at least 
two alternative promoters likely exist.  
The regulatory gene region contain several binding 
motifs for transcription factors including FoxO, 
p53, Egr, Smad, etc, which allow the coupling of 
DGKA expression with several signaling pathways. 
Identification of DGKA as a gene regulated by 
FoxO has contributed to explain its transcriptional 
downregulation in response to antigen stimulation 
and interleukin 2 (IL2) (Martinez-Moreno et al., 
2012). 
Protein 
Note 
The protein encoded by the DGKA gene (2.7.1.107) 
belongs to the eukaryotic diacylglycerol kinase 
family.  
It attenuates the second messenger diacylglycerol, 
that activates C1-containing proteins like members 
of the classical and novel PKCs, PKD, RasGRP and 
chimaerin families.  
It also produces phosphatidic acid, another lipid 
mediator that participates in the resynthesis of 
phosphatidylinositols and activates different 
proteins like mTOR or atypical PKCs. 
Description 
- The diacylglycerol kinases (DGK) are a family of 
signaling proteins that modulate diacylglycerol 
levels by catalyzing its conversion to phosphatidic 
acid (Merida et al., 2008). DGK belongs to a 
superfamily that also includes the recently 
identified bacterial DgkB as well as the sphingosine 
kinase (SPK) and ceramide kinase (CERK) 
families. Proteins in this superfamily share a 
common catalytic domain (DAGKc: Pfam00781). 
- In addition to the catalytic region, all DGK family 
members have at least two protein kinase C-like 
type 1 (C1) domains that, except for the first C1 
domain in DGKB and DGKG, lack the key residues 
that define a canonical phorbol ester/DAG-binding 
C1 domain (Shindo et al., 2003). 
- Mammals express ten DGK isoforms grouped into 
five subtypes; each DGK subtype has distinct 
regulatory motifs that suggest the existence of 
diverse regulatory mechanisms and/or participation 
in different signaling complexes. 
- Diacylglycerol Kinase alpha (DGKA) together 
with the beta (DGKB) and gamma (DGKG) 
isoforms represent the type I DGK, whose signature 
is the presence at the N-terminal region of a 
recoverin-like domain (RVH) and a tandem of EF 
hand motifs, characteristic of Ca2+-binding proteins. 
 
Figure 3. Distribution of conserved and specific regions in DGKA. C1, conserved protein kinase C-type 1 regions. Y218, 
Tyrosine phosphorylated by c-Abl. Y335, Tyrosine phosphorylated by Src and Lck. PPP Pro-rich region proposed to interact with 
Src. 
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Expression 
- DGKA is the only DGK isoform particularly 
enriched in the thymus and peripheral T 
lymphocytes. DGKA levels are tightly coupled to 
the differentiation and proliferation state of T 
lymphocytes. Quiescent, naïve T lymphocytes 
express high levels of DGKA that decrease rapidly 
in response to antigenic and IL2-derived signals 
(Martinez-Moreno et al., 2012). DGKA was 
identified as an anergy-induced gene (Macian et al., 
2002). Anergy represents an unresponsive state in T 
cells that is vital in immune system homeostasis 
and constitutes a means for avoiding response to 
self and thus, for preventing autoimmunity. Tumors 
also induce anergic-non responsive states in T cells. 
In agreement with this finding, DGKA-
overexpressing lymphocytes are "anergic" and no 
longer respond to antigenic stimuli (Zha et al., 
2006). On the contrary, T cells from DGKA 
deficient mice are resistant to anergy induction 
(Olenchock et al., 2006). 
- Recent studies have characterized miR-297 as a 
highly cytotoxic microRNA expressed in 
glioblastoma, with minimal cytotoxicity to normal 
astrocytes. DGKA is shown to be a miR-297 target 
with a critical role in miR-297 toxicity. These 
studies identify miR-297 as a novel and physiologic 
regulator of cancer cell survival, largely through 
targeting of DGKA (Kefas et al., 2013). 
Localisation 
- DGKA is a cytosolic enzyme that translocates to 
the membrane to phosphorylate diacylglycerol. The 
N-terminal region of DGKA, encompassing the 
Ca2+ regulatory elements has a negative regulatory 
role in enzyme activation and receptor-induced 
membrane localization, as shown by enhanced 
activity and constitutive plasma membrane 
localization of a mutant lacking this region 
(Sanjuan et al., 2001). In addition to Ca2+ 
generation, activation of Tyr kinases is required for 
membrane stabilization of DGKA (Sanjuan et al., 
2001). Tyr335 in the human sequence, located at 
the hinge between the C1 and the catalytic domains, 
was recently identified as an Lck-dependent DGKA 
phosphorylation site in T lymphocytes (Merino et 
al., 2008). 
- Membrane localization of DGKA in non-T cells 
requires Src-family tyrosine kinase activity and 
involves the association of DGKA with Src via a 
proline-rich sequence (Baldanzi et al., 2008). 
DGKA membrane localization and activation is 
required for cell motility, proliferation and 
angiogenesis, acting as a rheostat that sets the 
thresholds required for growth factor-induced 
migratory signals. 
- Recent reports have suggested nuclear localization 
for DGKA following serum starvation and 
demonstrated that DGKA relocates back to the 
cytosol in response to serum re-addition. Serum-
induced export requires c-Abl mediated Tyr-218 
phosphorylation (Matsubara et al., 2012). 
Function 
- The best characterized function for DGKA as a 
negative modulator of diacylglycerol-based 
signaling has been demonstrated in T lymphocytes. 
DGKA acts as a "switch-off" signal for Ras 
activation, mediated by localization to the 
membrane of Ras-GRP1 a GDP-exchanger for Ras 
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with a DAG-binding domain (Sanjuan et al., 2001; 
Sanjuan et al., 2003). 
- Contrary to its negative contribution to T cell 
responses, high DGKA expression in tumors 
appears to have a positive role in neoplastic 
transformation.  
DGKA-dependent PA generation contributes to 
melanoma survival through activation of the NFKB 
pathway (Yanagisawa et al., 2007). 
- DGKA mediated PA generation has been reported 
to participate in tumor migration and invasion. 
Generation of PA downstream of DGKA is 
essential to facilitate the Rab coupling protein 
(RCP)- mediated integrin recycling that is required 
for tumor cell invasion (Rainiero et al., 2012). 
Mutations 
Note 
V379I mutation in DGKA identified as a putative 
driver mutation for pancreatic cancer. 
Implicated in 
Lymphoma 
Note 
DGKA was found to be constitutively activated in 
nucleophosmin/anaplastic lymphoma kinase (NPM 
/ ALK) fusion in malignant lymphomas, where 
inhibition of DGKA significantly reduced tumor 
growth (Bacchiocchi et al., 2005). 
Melanoma 
Note 
DGKA has been implicated in suppression of TNF-
alpha induced apoptosis of human melanoma cells 
via NF-KB (Yanagisawa et al., 2005). 
Hepatocellular carcinoma 
Note 
DGKA is absent in hepatocytes but it is expressed 
in different hepatocellular carcinoma cell lines. 
DGKA is found expressed in cancerous tissue but 
not in the adjacent non-cancerous hepatocytes.  
High DGKA expression associates with high Ki67 
expression and a high rate of HCC recurrence 
(p=0.033) following surgery.  
In multivariate analyses, high DGKA expression is 
found as an independent factor for determining 
HCC recurrence after surgery (Takeishi et al., 
2012). 
Pancreatic carcinoma 
Note 
Using CHASM (Cancer-specific High-throughput 
Annotation of Somatic Mutations) V379I mutation 
in DGKA was found as a putative driver mutation 
for pancreatic cancer (Carter et al., 2010). 
Glioblastoma 
Note 
Recent studies have described DGKA as an 
important component of malignant transformation 
in glioblastoma (Dominguez et al., 2013).  
Impaired DGKA activity through siRNA targeting 
or the use of small-molecule inhibitors induced 
caspase-mediated apoptosis in glioblastoma cells, 
but lacked toxicity in noncancerous cells. 
Lung cancer 
Note 
Survival trees in a study involving the expression 
profiles of 3588 genes in 211 lung adenocarcinoma 
patients identified DGKA as a marker for good 
survival in a group of advanced-stage patients with 
remarkably good survival outcome (Berrar et al., 
2005). 
X-linked proliferative disease 
Note 
Studies have reported DGKA inhibition by the 
adaptor protein SAP (Baldanzi et al., 2011). Loss-
of-function SAP mutations cause X-linked 
lymphoproliferative disease (XLP), an immune 
disorder characterized by a deregulated immune 
response to Epstein-Barr virus, susceptibility to 
lymphoma and defective antibody production. 
Impaired regulation of DGKA activity in SAP-
deficient lymphocytes may contribute to their 
defective TCR-induced responses, suggesting that 
pharmacological inhibition of DGKA could be 
useful in the treatment of certain manifestations of 
XLP. 
CD8 tumor infiltrates 
Note 
DGKA was found to be more highly expressed in 
CD8-tumor infiltrates T cells (TILs) in renal 
carcinoma that in circulating CD8 cells (Prinz et al., 
2012).  
Low dose treatment of TILs with IL2 reduced 
DGKA protein levels, improved stimulation-
induced ERK and AKT phosphorylation, and 
increased the number of degranulating CD8-TILs. 
DGKA inhibition could be a novel strategy to 
enhance anti-tumor CD8 T cells response and may 
help prevent inactivation of adoptively transferred 
T cells improving therapeutic efficacy. 
Localized aggressive periodontitis 
(LAP) 
Note 
Localized aggressive periodontitis (LAP) is a 
familial disorder characterized by destruction of the 
supporting structures of dentition.  
Microarray and kinetic-PCR analysis revealed  
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diminished RNA expression of DGKA in 
neutrophils from LAP patients compared with 
asymptomatic individuals (Gronert et al., 2004). 
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